CHF 260.3
Key Takeaways
Risk factor
Negligible price volatility
Profitability factor
Very strong margins and returns
About
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and internationally. The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation....
Company Valuation
Considering past and projected metrics, the stock is slightly 'cheaper' than its peers. Specifically, the stock is fairly valued on P/E, neutral on EV/EBITDA, underpriced
Target Price
The average target price of ROG.SW is 286 and suggests 10% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendation
